Consensus PTC Therapeutics, Inc.

Equities

PTCT

US69366J2006

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
36.36 ^USD	+1.54%		-2.26%	+31.93%

May. 24	Ptc Therapeutics Insider Sold Shares Worth $764,800, According to a Recent SEC Filing	MT
May. 21	Goldman Sachs Adjusts PTC Therapeutics Price Target to $32 From $18, Maintains Sell Rating	MT

Evolution of the average Target Price on PTC Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

0f618cbf5e1be6280fa.UupFFu5ZnP_iZIIRnMNDpBRV8bOFjtbJ-DN_wyUwRrw.NJt9IKoJ05e1HLpB_poh4G0nyOnCxpinlko3tVVvE_Zn2zV63Azdjs9W2w~da9947d57673b7555b676237babc9ef9

Analyst Recommendations on PTC Therapeutics, Inc.

Ptc Therapeutics Insider Sold Shares Worth $764,800, According to a Recent SEC Filing	May. 24	MT
Goldman Sachs Adjusts PTC Therapeutics Price Target to $32 From $18, Maintains Sell Rating	May. 21	MT
Raymond James Upgrades PTC Therapeutics to Market Perform From Underperform	May. 20	MT
Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28	Apr. 29	MT
TD Cowen Cuts Price Target on PTC Therapeutics to $30 From $32, Maintains Market Perform Rating	Mar. 01	MT
RBC Raises Price Target on PTC Therapeutics to $28 From $22, Keeps Sector Perform Rating	Mar. 01	MT
Cantor Fitzgerald Cuts PTC Therapeutics' Price Target to $45 From $51, Keeps Overweight Rating	Jan. 26	MT
Inflation is just the icing on the cake	Jan. 26
RBC Cuts Price Target on PTC Therapeutics to $22 From $27 Amid Negative Opinion on Translarna From European Medicines Agency Committee; Sector Perform Kept	Jan. 26	MT
RBC Raises Price Target on PTC Therapeutics to $27 From $23, Keeps Sector Perform Rating	Jan. 03	MT
Morgan Stanley Downgrades PTC Therapeutics to Underweight From Equalweight, Price Target is $28	Dec. 19	MT
North American Morning Briefing : Rate Decisions, -2-	23-10-30	DJ
Morgan Stanley Adjusts Price Target on PTC Therapeutics to $28 From $31, Maintains Equalweight Rating	23-10-27	MT
Barclays Trims Price Target on PTC Therapeutics to $25 From $26, Maintains Equalweight Rating	23-10-27	MT
Citigroup Downgrades PTC Therapeutics to Sell From Neutral	23-10-27	MT
RBC Cuts Price Target on PTC Therapeutics to $23 From $26, Keeps Sector Perform Rating	23-10-27	MT
Truist Securities Downgrades PTC Therapeutics to Hold From Buy, Price Target is $25	23-10-06	MT
Barclays Lowers Price Target on PTC Therapeutics to $26 From $44, Maintains Equalweight Rating	23-09-18	MT
Goldman Sachs Adjusts Price Target on PTC Therapeutics to $22 From $35, Keeps Sell Rating	23-09-18	MT
RBC Cuts Price Target on PTC Therapeutics to $26 From $49 Amid Negative Opinion on Translarna From European Medicines Agency Committee; Sector Perform Kept	23-09-18	MT
Citigroup Downgrades PTC Therapeutics to Neutral From Buy, Cuts Price Target to $29 From $55	23-09-18	MT
JPMorgan Lowers PTC Therapeutics Price Target to $53 From $70, Maintains Overweight Rating	23-09-15	MT
Morgan Stanley Cuts Price Target on PTC Therapeutics to $31 From $47, Maintains Equalweight Rating	23-09-15	MT
Truist Securities Lowers Price Target on PTC Therapeutics to $60 From $65, Maintains Buy Rating	23-09-15	MT
TD Cowen Cuts Price Target on PTC Therapeutics to $35 From $40, Maintains Market Perform Rating	23-09-15	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

36.36 USD

Average target price

36.73 USD

Spread / Average Target

+1.01%

High Price Target

53 USD

Spread / Highest target

+45.76%

Low Price Target

25 USD

Spread / Lowest Target

-31.24%

Consensus detail

Consensus revision (last 18 months)

Analysts covering PTC Therapeutics, Inc.

Goldman Sachs
Raymond James
Morgan Stanley
TD Cowen
RBC Capital Markets
Cantor Fitzgerald
Barclays
Citigroup
Truist Securities
JPMorgan Chase
UBS
Credit Suisse
BofA Securities
SVB Securities LLC
Jefferies & Co.

Ratings for PTC Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar